Results 101 to 110 of about 20,867 (266)

Diabetes and menopause: A critical yet neglected intersection

Diabetic Medicine, EarlyView.
Isabell Haage, David Studer, Petra Stute, Lia Bally   +3 more
wiley   +1 more source

Cardiovascular Efficacy of GLP‐1 Receptor Agonists by Kidney Function: An Updated Meta‐Analysis of Randomized Trials Including the SOUL Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the cardiovascular efficacy and absolute benefit of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) by baseline estimated glomerular filtration rate (eGFR). Materials and Methods PubMed and EMBASE were searched to 29 April 2026 for randomized placebo‐controlled trials of GLP‐1RAs in adults with type 2 diabetes or ...
Masashi Hasebe, Chen‐Yang Su, Daisuke Yabe, Satoshi Yoshiji   +3 more
wiley   +1 more source

GLP‐1‐Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Individuals living with type 1 diabetes (T1D) are at increased risk for cardiovascular (CV) and renal complications, yet therapeutic strategies specifically targeting cardiorenal risk reduction in this population remain limited. The role of glucagon‐like peptide‐1 (GLP‐1)‐based therapies in T1D remains unclear.
Anastasios Tentolouris, Djordje S. Popovic, Alexandros L. Liarakos, Alexandros Briasoulis, Nikolaos Papanas, Theocharis Koufakis   +5 more
wiley   +1 more source

Positioning Incretin‐Based and Next‐Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta‐Analyses

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background The obesity pharmacotherapy landscape is evolving rapidly, with several approved incretin‐based therapies and an expanding pipeline of investigational compounds targeting multiple metabolic pathways. Conventional evidence syntheses often struggle to accommodate differences in dose selection, treatment duration and stage of clinical ...
Matteo Monami, Benedetta Ragghianti, Edoardo Mannucci   +2 more
wiley   +1 more source

Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE‐O Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims In the AMPLITUDE O trial, efpeglenatide reduced major cardiovascular events by 27% in 4076 individuals with Type 2 diabetes and established cardiovascular or kidney disease compared to placebo during a median follow‐up of 1.81 years. This exploratory mediation analysis evaluates the degree to which changes in measured clinical variables ...
Daniel Raaschou‐Oddershede, Christine R. Schwarz, Tanya Kovalova, Kelley R. Branch, Stefano Del Prato, Carolyn S. P. Lam, Renato D. Lopes, Richard Pratley, Julio Rosenstock, Naveed Sattar, Hertzel C. Gerstein   +10 more
wiley   +1 more source

Tirzepatide for Excess Weight in Adults With Type 1 Diabetes Using MiniMed 780G

Diabetes, Obesity and Metabolism, EarlyView.
Michelantonio De Fano, Rachele Tortoriello, Stefania Rucco, Sofia Corio, Marcello Manco, Edoardo Guerrini, Francesca Porcellati   +6 more
wiley   +1 more source

Tirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the effect of tirzepatide on body weight, glycaemic control, insulin requirements, continuous glucose monitoring (CGM) metrics and cardiorenal parameters in adults with Type 1 diabetes (T1D) and overweight or obesity. Materials and Methods In this retrospective matched cohort study, adults with T1D, BMI ≥ 27 kg/m2, CGM use and
Amanda R. Purcell, Matilda S. G. Longfield, Natassia Rodrigo, Sarah J. Glastras   +3 more
wiley   +1 more source

Early Weight Regain After GLP‐1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De‐Escalation Strategies

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have transformed the pharmacological management of obesity, producing substantial and sustained weight loss during active treatment. However, discontinuation of therapy is frequently followed by significant weight regain, raising important questions regarding the durability of treatment ...
M. A. Damhof, F. H. van Bruggen, E. N. van Roon   +2 more
wiley   +1 more source

Diagnosis and management of equine metabolic syndrome

Equine Veterinary Education, EarlyView.
Summary Equine metabolic syndrome (EMS) is a prevalent endocrine disorder that increases the risk of hyperinsulinaemia‐associated laminitis (HAL), the most common and clinically significant form of laminitis. The central pathological feature of EMS is insulin dysregulation (ID), which encompasses basal or postprandial hyperinsulinaemia and tissue ...
F. R. Bertin
wiley   +1 more source

Effectiveness of tirzepatide in Japanese patients with type 2 diabetes but no obesity: A sub‐analysis of Hokkaido‐TZP study data

Journal of Diabetes Investigation, EarlyView.
Tirzepatide achieved significant HbA1c reduction in Japanese patients with type 2 diabetes without obesity, regardless of baseline BMI. Weight reduction was BMI‐dependent and enhanced by dietary consultations. No patient developed underweight status during the 6‐month observation period.
Tomoe Abe, Fumika Maruyama, Eisuke Nishikawa, Miki Ito, Yukie Miyano, Hiroki Yamagata, Taiga Sasaki, Hidemitsu Sakagami, Akinobu Nakamura, Hiroshi Nomoto, on behalf of the Hokkaido‐TZP Study Group   +10 more
wiley   +1 more source